Abbott Laboratories (NYSE:ABT) shares, rose in value on Friday, November 01, with the stock price up by 5.15% to the previous day’s close as strong demand from buyers drove the stock to $119.21.
Actively observing the price movement in the recent trading, the stock is buoying the session at $113.37, falling within a range of $117.095 and $119.92. The value of beta (5-year monthly) is 0.722 whereas the PE ratio is 36.22 over 12-month period. Referring to stock’s 52-week performance, its high was $121.64, and the low was $92.43. On the whole, ABT has fluctuated by 6.22% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
With the market capitalization of Abbott Laboratories currently standing at about $207.41 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Jan-22. The company’s Forward Dividend Ratio is 2.20, with its dividend yield at 1.85%.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 42.01B, with a low estimate of 10.87B and a high estimate of 11.21B. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 11.04B.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ABT’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 4.02, with the price of ABT currently trading nearly 2.79% and 3.72% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.22, while the 7-day volatility ratio is showing 1.64% which for the 30-day chart, stands at 1.53%. Furthermore, Abbott Laboratories (ABT)’s beta value is 0.72, and its average true range (ATR) is 2.15.
A comparison of Abbott Laboratories (ABT) with its peers suggests the former has fared considerably weaker in the market. ABT showed an intraday change of 5.15% in today’s session so far, and over the past year, it grew by 25.47%%.
Data on historical trading for Abbott Laboratories (NYSE:ABT) indicates that the trading volumes over the past 10 days have averaged 5.3 and over the past 3 months, they’ve averaged 5.04 million. According to company’s latest data on outstanding shares, there are 1.73 billion shares outstanding.
Nearly 0.66% of Abbott Laboratories’s shares belong to company insiders and institutional investors own 76.93% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 13.98 million shares as on 2024-10-15, resulting in a short ratio of 2.87. According to the data, the short interest in Abbott Laboratories (ABT) stood at 81.00 of shares outstanding as of 2024-10-15; the number of short shares registered in 2024-09-13 reached 13.36 million. The stock has risen by 8.30% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABT stock heading into the next quarter.
